(S (NP-SBJ Tyloxapol/NN) (VP-COOD (VP inhibits/VBZ (NP (NP-COOD (NP NF-kappa/NN B/NN) and/CC (NP cytokine/NN)) release/NN)) ,/, (VP scavenges/VBZ (NP HOCI/NN)) ,/, and/CC (VP reduces/VBZ (NP (NP viscosity/NN) (PP of/IN (NP cystic/JJ fibrosis/NN sputum/NN))))) ./.)
(S (NP-SBJ (NP (NP Cystic/JJ fibrosis/NN) (PRN -LRB-/-LRB- (NP CF/NN) -RRB-/-RRB-)) patients/NNS) (VP develop/VB (NP (NP progressive/JJ cytokine-mediated/JJ inflammatory/JJ lung/NN disease/NN) ,/, (PP with/IN (NP (NP abundant/JJ production/NN) (PP of/IN (NP (NP (ADJP-COOD (ADJP thick/JJ) ,/, (ADJP tenacious/JJ) ,/, (ADJP-COOD (ADJP (NP protease-/NN) (ADJP *?*/-NONE-)) and/CC (ADJP oxidant-rich/JJ))) purulent/JJ airway/NN secretions/NNS) (SBAR (WHNP-20 that/WDT) (S (NP-SBJ *T*-20/-NONE-) (VP are/VBP (ADJP-PRD difficult/JJ (SBAR (WHNP-21 0/-NONE-) (S (NP-SBJ */-NONE-) (VP to/TO (VP clear/VB (NP *T*-21/-NONE-) (PP even/RB with/IN (NP physiotherapy/NN)))))))))))))))) ./.)
(S (PP In/IN (NP (NP the/DT search/NN) (PP for/IN (NP a/DT potential/JJ treatment/NN)))) ,/, (NP-SBJ we/PRP) (VP have/VBP (VP tested/VBN (NP (NP tyloxapol/NN) ,/, (NP (NP an/DT alkylaryl/NN polyether/JJ alcohol/NN polymer/NN detergent/NN) (VP (ADVP-TMP previously/RB) used/VBN (NP */-NONE-) (PP as/IN (NP a/DT mucolytic/JJ agent/NN)) (PP in/IN (NP adult/JJ chronic/JJ bronchitis/NN))))))) ./.)
(S (NP-SBJ Tyloxapol/NN) (VP-COOD (VP inhibits/VBZ (NP (NP activation/NN) (PP of/IN (NP the/DT transcription/NN factor/NN (NP (NP nuclear/JJ factor-kappa/NN B/NN) (PRN -LRB-/-LRB- (NP NK-kappa/NN B/NN) -RRB-/-RRB-)))))) ,/, (VP reduces/VBZ (NP (NP resting/VBG secretion/NN) (PP of/IN (NP (NP the/DT cytokine/NN (NP (NP interleukin-8/NN) (PRN -LRB-/-LRB- (NP IL-8/NN) -RRB-/-RRB-))) (PP in/IN (NP cultured/VBN human/JJ monocytes/NNS)))))) ,/, and/CC (VP inhibits/VBZ (NP (NP (ADJP lipopolysaccharide/NN -LRB-/-LRB- LPS/NN -RRB-/-RRB- -stimulated/JJ) release/NN) (PP of/IN (NP-COOD (NP (NP tumor/NN necrosis/NN factor-alpha/NN) (PRN -LRB-/-LRB- (NP TNF-alpha/NN) -RRB-/-RRB-)) ,/, (NP IL-1/NN beta/NN) ,/, (NP IL-6/NN) ,/, (NP IL-8/NN) ,/, (NP (NP granulocyte-macrophage/JJ colony-stimulating/JJ factor/NN) (PRN -LRB-/-LRB- (NP GM-CSF/NN) -RRB-/-RRB-)) ,/, and/CC (NP the/DT eiconsanoids/NNS (NP-COOD (NP thromboxane/NN A2/NN) and/CC (NP (NP leukotriene/NN B4/NN) (PRN -LRB-/-LRB- (NP LTB4/NN) -RRB-/-RRB-))))))))) ./.)
(S (NP-SBJ We/PRP) (VP have/VBP (ADVP-TMP previously/RB) (VP shown/VBN (SBAR that/IN (S (NP-SBJ tyloxapol/NN) (VP is/VBZ (NP-PRD (NP a/DT potent/JJ antioxidant/NN) (PP for/IN (NP (NP hydroxyl/NN radicals/NNS) (PRN -LRB-/-LRB- (NP OH/NN) -RRB-/-RRB-))))))))) ./.)
(S (NP-SBJ (NP Tyloxapol/NN) (PRN -LRB-/-LRB- (NP (ADJP (QP 0.05/CD to/TO 0.1/CD) %/NN) wt\/vol/NN) -RRB-/-RRB-)) (ADVP effectively/RB) (VP-COOD (VP scavenges/VBZ (NP (NP the/DT oxidant/JJ hypochlorous/JJ acid/NN) (PRN -LRB-/-LRB- (NP (NP HOCl/NN) ;/: (NP (QP 1/CD to/TO 7.5/CD) mM/NN)) -RRB-/-RRB-)) (ADVP in/FW vitro/FW)) ,/, and/CC (VP protects/VBZ (PP from/IN (NP HOCl-mediated/JJ lung/NN injury/NN)) (PP in/IN (NP rats/NNS)))) ./.)
(S (NP-SBJ Tyloxapol/NN) (ADVP also/RB) (VP reduces/VBZ (NP (NP the/DT viscosity/NN) (PP of/IN (NP CF/NN sputum/NN))) -LRB-/-LRB- (PP from/IN (NP (QP 463/CD +\/-/CC 133/CD) (NP *RNR*-100/-NONE-))) (PP to/TO (NP (QP 128/CD +\/-/CC 52/CD) (NP *RNR*-100/-NONE-))) (NP-100 centipoise/NN) -RRB-/-RRB-) ./.)
(S (NP-SBJ We/PRP) (VP conclude/VBP (SBAR that/IN (S (NP-SBJ tyloxapol/NN) (VP-COOD (VP is/VBZ (ADVP potentially/RB) (ADJP-PRD useful/JJ (PP as/IN (NP (NP a/DT new/JJ antiinflammatory/JJ therapy/NN) (PP for/IN (NP CF/NN lung/NN disease/NN)))))) ,/, and/CC (VP could/MD (ADVP possibly/RB) (VP promote/VB (NP (NP clearance/NN) (PP of/IN (NP secretions/NNS)) (PP in/IN (NP the/DT CF/NN airway/NN))))))))) ./.)
